The proposed EU-wide restriction on per- and polyfluoroalkyl substances has entered a decisive phase. In March 2026, ECHA’s Risk Assessment Committee adopted its final opinion, while the Socio-Economic Analysis Committee agreed on its draft opinion. Both support a broad restriction on the manufacture, marketing, and use of PFAS, but also recognize that targeted, time-limited derogations may be needed where suitable alternatives are not yet available.

The process has therefore moved beyond the original choice between a complete ban and unrestricted continued use. The emerging approach combines substitution, emission controls, and limited exemptions for critical industrial applications. The European Commission has indicated that consumer uses may face the strongest controls, while certain essential industrial uses could continue temporarily under strict conditions. ECHA is expected to complete its scientific assessment by the end of 2026, after which the Commission will prepare the formal restriction proposal for consideration by Member States.

For businesses, the main implication is that derogations should not be treated as permanent exemptions. Companies using PFAS in electronics, medical technologies, energy systems, transport, or specialized manufacturing should document technical necessity, emissions, available alternatives, and substitution timelines. The restriction is likely to accelerate product redesign and supply-chain disclosure while creating significant compliance challenges where PFAS are present in complex components or difficult-to-trace processing aids.